Impact of matrix metalloproteinases on inhibition of mineralization by fetuin

Journal of Periodontal Research

Volumn 48, Issue 3, 2013, Pages 357-366

  Schure, R ^a   Costa, K D ^a   Rezaei, R ^a   Lee, W ^a   Laschinger, C ^a   Tenenbaum, H C ^a   Mcculloch, C A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Calcium phosphate; Matrilysin; Mineralization; Periodontal diseases; Stromelysin

Indexed keywords

FETUIN A; HYDROXYAPATITE; MATRILYSIN; STROMELYSIN;

ARTICLE; BLOOD VESSEL CALCIFICATION; CELL FREE SYSTEM; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MASS SPECTROMETRY; METABOLISM; NONPARAMETRIC TEST; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING;

ALPHA-2-HS-GLYCOPROTEIN; CELL-FREE SYSTEM; DURAPATITE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MASS SPECTROMETRY; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; PROTEIN BINDING; STATISTICS, NONPARAMETRIC; VASCULAR CALCIFICATION;

EID: 84876786455     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/jre.12015     Document Type: Article

References (68)

1. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 2005;96:717-722.
2. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004;15:2959-2964.
3. Beck JD, Slade G, Offenbacher S. Oral disease, cardiovascular disease and systemic inflammation. Periodontol 2000 2000;23:110-120.
4. Behle JH, Papapanou PN. Periodontal infections and atherosclerotic vascular disease: an update. Int Dent J 2006;56:256-262.
5. Demmer RT, Desvarieux M. Periodontal infections and cardiovascular disease: the heart of the matter. J Am Dent Assoc 2006;137(suppl):14S-20S.quiz 38S.
6. Humphrey LL, Fu R, Buckley DI, Freeman M, Helfand M. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. J Gen Intern Med 2008;23:2079-2086.
7. Khader YS, Albashaireh ZS, Alomari MA. Periodontal diseases and the risk of coronary heart and cerebrovascular diseases: a meta-analysis. J Periodontol 2004;75:1046-1053.
8. Guimaraes Henriques JC, Kreich EM, Helena Baldani M, Luciano M, Cezar de Melo Castilho J, Cesar de Moraes L. Panoramic radiography in the diagnosis of carotid artery atheromas and the associated risk factors. Open Dent J 2011;5:79-83.
9. Lockhart PB, Bulger AF, Papapanou PN et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation 2012;125:2520-2544.
10. Speer MY, Giachelli CM. Regulation of cardiovascular calcification. Cardiovasc Pathol 2004;13:63-70.
11. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004;24:1161-1170.
12. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
13. Jahnen-Dechent W, Schafer C, Heiss A, Grotzinger J. Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. Z Kardiol 2001;90(suppl 3):47-56.
14. Schafer C, Heiss A, Schwarz A et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-366.
15. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118-1129.
16. Matsushima K, Cheng M, Migita S. Purification and physicochemical characterization of human alpha 2-HS-glycoprotein. Biochim Biophys Acta 1982;701:200-205.
17. Kellermann J, Haupt H, Auerswald EA, Muller-Ester W. The arrangement of disulfide loops in human alpha 2-HS glycoprotein Similarity to the disulfide bridge structures of cystatins and kininogens. J Biol Chem 1989;264:14121-14128.
18. Triffitt JT, Gebauer U, Ashton BA, Owen ME, Reynolds JJ. Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature 1976;262:226-227.
19. Daveau M, Christian D, Julen N, Hiron M, Arnaud P, Lebreton JP. The synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 1988;241:191-194.
20. Triffitt JT, Owen ME, Ashton BA, Wilson JM. Plasma disappearance of rabbit alpha2HS-glycoprotein and its uptake by bone tissue. Calcif Tissue Res 1978;26:155-161.
21. Colclasure GC, Lloyd WS, Lamkin M et al. Human serum alpha 2HS-glycoprotein modulates in vitro bone resorption. J Clin Endocrinol Metab 1988;66:187-192.
22. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells A possible role in mineralization and calcium homeostasis. J Biol Chem 1996;271:20789-20796.
23. Heiss A, DuChesne A, Denecke B et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A Formation of colloidal calciprotein particles. J Biol Chem 2003;278:13333-13341.
24. Heiss A, Eckert T, Aretz A et al. Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem 2008;283:14815-14825.
25. Heiss A, Jahnen-Dechent W, Endo H, Schwahn D. Structural dynamics of a colloidal protein-mineral complex bestowing on calcium phosphate a high solubility in biological fluids. Biointerphases 2007;2:16-20.
26. Binkert C, Demetriou M, Sukhu B, Szweras M, Tenenbaum HC, Dennis JW. Regulation of osteogenesis by fetuin. J Biol Chem 1999;274:28514-28520.
27. Szweras M, Liu D, Partridge EA et al. alpha 2-HS glycoprotein/fetuin a transforming growth factor-beta/bone morphogenetic protein antagonist regulates postnatal bone growth remodeling. J Biol Chem 2002;277:19991-19997.
28. Rittenberg B, Partridge E, Baker G et al. Regulation of BMP-induced ectopic bone formation by Ahsg. J Orthop Res 2005;23:653-662.
29. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996;271:12755-12761.
30. Reynolds JL, Skepper JN, McNair R et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005;16:2920-2930.
31. Soder PO, Meurman JH, Jogestrand T, Nowak J, Soder B. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in blood as markers for early atherosclerosis in subjects with chronic periodontitis. J Periodontal Res 2009;44:452-458.
32. Nakashima K, Giannopoulou C, Andersen E et al. A longitudinal study of various crevicular fluid components as markers of periodontal disease activity. J Clin Periodontol 1996;23:832-838.
33. Nakashima K, Roehrich N, Cimasoni G. Osteocalcin, prostaglandin E2 and alkaline phosphatase in gingival crevicular fluid: their relations to periodontal status. J Clin Periodontol 1994;21:327-333.
34. Harper DS, Lamster IB, Celenti R. Relationship of subgingival plaque flora to lysosomal and cytoplasmic enzyme activity in gingival crevicular fluid. J Clin Periodontol 1989;16:164-169.
35. Loos BG, Tjoa S. Host-derived diagnostic markers for periodontitis: do they exist in gingival crevice fluid? Periodontol 2000 2005;39:53-72.
36. McCulloch CA. Host enzymes in gingival crevicular fluid as diagnostic indicators of periodontitis. J Clin Periodontol 1994;21:497-506.
37. Imrey PB, Crawford JM, Cohen RL, Alves ME, McSwiggin TA, Chambers DA. A cross-sectional analysis of aspartate aminotransferase in human gingival crevicular fluid. J Periodontal Res 1991;26:75-84.
38. Persson GR, DeRouen TA, Page RC. Relationship between levels of aspartate aminotransferase in gingival crevicular fluid and gingival inflammation. J Periodontal Res 1990;25:17-24.
39. Persson GR, Page RC. Diagnostic characteristics of crevicular fluid aspartate aminotransferase (AST) levels associated with periodontal disease activity. J Clin Periodontol 1992;19:43-48.
40. Lamster IB, Ahlo JK. Analysis of gingival crevicular fluid as applied to the diagnosis of oral and systemic diseases. Ann N Y Acad Sci 2007;1098:216-229.
41. Lamster IB, Oshrain RL, Harper DS, Celenti RS, Hovliaras CA, Gordon JM. Enzyme activity in crevicular fluid for detection and prediction of clinical attachment loss in patients with chronic adult periodontitis. Six month results. J Periodontol 1988;59:516-523.
42. Gustafsson A, Asman B, Bergstrom K, Soder PO. Granulocyte elastase in gingival crevicular fluid A possible discriminator between gingivitis and periodontitis. J Clin Periodontol 1992;19:535-540.
43. Palcanis KG, Larjava IK, Wells BR et al. Elastase as an indicator of periodontal disease progression. J Periodontol 1992;63:237-242.
44. Alpagot T, Bell C, Lundergan W, Chambers DW, Rudin R. Longitudinal evaluation of GCF MMP-3 and TIMP-1 levels as prognostic factors for progression of periodontitis. J Clin Periodontol 2001;28:353-359.
45. Haerian A, Adonogianaki E, Mooney J, Docherty JP, Kinane DF. Gingival crevicular stromelysin, collagenase and tissue inhibitor of metalloproteinases levels in healthy and diseased sites. J Clin Periodontol 1995;22:505-509.
46. Unemori EN, Bair MJ, Bauer EA, Amento EP. Stromelysin expression regulates collagenase activation in human fibroblasts Dissociable control of two metalloproteinases by interferon-gamma. J Biol Chem 1991;266:23477-23482.
47. Emingil G, Tervahartiala T, Mantyla P, Maatta M, Sorsa T, Atilla G. Gingival crevicular fluid matrix metalloproteinase (MMP)-7, extracellular MMP inducer, and tissue inhibitor of MMP-1 levels in periodontal disease. J Periodontol 2006;77:2040-2050.
48. Tervahartiala T, Pirila E, Ceponis A et al. The in vivo expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and localized juvenile periodontitis. J Dent Res 2000;79:1969-1977.
49. Lee W, Aitken S, Kulkarni G et al. Collagenase activity in recurrent periodontitis: relationship to disease progression and doxycycline therapy. J Periodontal Res 1991;26:479-485.
50. Yeh YC, Sheu BS, Cheng HC, Wang YL, Yang HB, Wu JJ. Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci 2010;55:1649-1657.
51. Ochieng J, Warfield P, Green B. Interactions of gelatinases with soluble and immobilized fetuin and asialofetuin. Arch Biochem Biophys 1995;322:250-255.
52. Ochieng J, Green B. The interactions of alpha 2HS glycoprotein with metalloproteinases. Biochem Mol Biol Int 1996;40:13-20.
53. Jahnen-Dechent W, Trindl A, Godovac-Zimmermann J, Muller-Esterl W. Posttranslational processing of human alpha 2-HS glycoprotein (human fetuin). Evidence for the production of a phosphorylated single-chain form by hepatoma cells. Eur J Biochem 1994;226:59-69.
54. Kubler D, Gosenca D, Wind M et al. Proteolytic processing by matrix metalloproteinases and phosphorylation by protein kinase CK2 of fetuin-A, the major globulin of fetal calf serum. Biochimie 2007;89:410-418.
55. Sung JY, Park SM, Lee CH et al. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J Biol Chem 2005;280:25216-25224.
56. Nawratil P, Lenzen S, Kellermann J et al. Limited proteolysis of human alpha2-HS glycoprotein/fetuin Evidence that a chymotryptic activity can release the connecting peptide. J Biol Chem 1996;271:31735-31741.
57. Romanelli R, Mancini S, Laschinger C, Overall CM, Sodek J, McCulloch CA. Activation of neutrophil collagenase in periodontitis. Infect Immun 1999;67:2319-2326.
58. Pikul S, McDow Dunham KL, Almstead NG et al. Discovery of potent, achiral matrix metalloproteinase inhibitors. J Med Chem 1998;41:3568-3571.
59. Chen CC, Boskey AL, Rosenberg LC. The inhibitory effect of cartilage proteoglycans on hydroxyapatite growth. Calcif Tissue Int 1984;36:285-290.
60. Cuisinier F, Bres EF, Hemmerle J, Voegel JC, Frank RM. Transmission electron microscopy of lattice planes in human alveolar bone apatite crystals. Calcif Tissue Int 1987;40:332-338.
61. Dziegielewska KM, Brown WM, Casey SJ et al. The complete cDNA and amino acid sequence of bovine fetuin Its homology with alpha 2HS glycoprotein and relation to other members of the cystatin superfamily. J Biol Chem 1990;265:4354-4357.
62. Cawston TE. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 1996;70:163-182.
63. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
64. Cotti E, Dessi C, Piras A, Mercuro G. Can a chronic dental infection be considered a cause of cardiovascular disease? A review of the literature Int J Cardiol 2011;148:4-10.
65. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol 2010;6:681-694.
66. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol 2009;53:317-333.
67. Albilia JB, Tenenbaum HC, Clokie CM et al. Serum levels of BMP-2, 4, 7 and AHSG in patients with degenerative joint disease requiring total arthroplasty of the hip and temporomandibular joints. J Orthop Res 2012. In press.
68. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001;276:41279-41287.